

THE LANCET

Haematology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Spivak JL. Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now? *Lancet Haematol* 2020; published online Jan 23. [https://doi.org/10.1016/S2352-3026\(19\)30262-5](https://doi.org/10.1016/S2352-3026(19)30262-5).

References

- Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. *N Engl J Med* 1981; **304**: 441-447.
- Gruppo Italiano SP. Polycythemia vera: the natural history of 1213 patients followed for 20 years. *Ann Intern Med* 1995; **123**: 656-664.
- Najean Y and Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. *Blood* 1997; **90**: 3370-3377.
- Thoennissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. *Blood* 2010; **115**: 1049-1053.
- Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. *Blood* 2013; **121**: 4778-4781.